---
audienceLevel: patient
cancerTypes:
- general
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Ciltacabtagene Autoleucel - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/ciltacabtagene-autoleucel
version: v1
---

# Ciltacabtagene Autoleucel - NCI

# Ciltacabtagene Autoleucel

Placeholder slot

(SIL-tuh-KAB-tuh-jeen AW-toh-LOO-sel)

This page contains brief information about ciltacabtagene autoleucel
and a collection of links to more information about the use of
this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Carvykti

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d040b91-3fb8-41db-ba7f-60a36f06e2c2&audience=consumer)

## Use in Cancer

Ciltacabtagene autoleucel
is approved to treat:

- **[multiple myeloma](/Common/PopUps/popDefinition.aspx?id=45793&version=Patient&language=English)** that has come back or did not respond to treatment. It is used in adults who have received at least one line of treatment that included a [proteasome inhibitor](/Common/PopUps/popDefinition.aspx?id=393541&version=Patient&language=English) and an [immunomodulating agent](/Common/PopUps/popDefinition.aspx?id=739791&version=Patient&language=English) and whose cancer did not respond to treatment with [lenalidomide](/Common/PopUps/popDefinition.aspx?id=393761&version=Patient&language=English)

Ciltacabtagene autoleucel
is only available as part of a special program called Carvykti REMS ([Risk Evaluation and Mitigation Strategies](https://www.carvyktirems.com/#Main)).

## More About Ciltacabtagene Autoleucel

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/792630) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Ciltacabtagene Autoleucel](https://medlineplus.gov/druginfo/meds/a622041.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[Understanding the Risk of Second Cancers After CAR T-Cell Therapy](https://www.cancer.gov/news-events/cancer-currents-blog/2024/car-t-cell-therapy-second-cancers)

[Targeted Therapy to Treat Cancer](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

[Carvykti Approval Marks Second CAR T-Cell Therapy for Multiple Myeloma](https://www.cancer.gov/news-events/cancer-currents-blog/2022/fda-carvykti-multiple-myeloma)

[T-cell Transfer Therapy](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/t-cell-transfer-therapy)

[CAR T Cells: Engineering Patientsâ€™ Immune Cells to Treat Their Cancers](https://www.cancer.gov/about-cancer/treatment/research/car-t-cells)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Ciltacabtagene Autoleucel](https://www.cancer.gov/research/participate/clinical-trials/intervention/C148498) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
